479 related articles for article (PubMed ID: 22535154)
1. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
Menzies AM; Haydu LE; Visintin L; Carlino MS; Howle JR; Thompson JF; Kefford RF; Scolyer RA; Long GV
Clin Cancer Res; 2012 Jun; 18(12):3242-9. PubMed ID: 22535154
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
3. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.
Ascierto PA; Minor D; Ribas A; Lebbe C; O'Hagan A; Arya N; Guckert M; Schadendorf D; Kefford RF; Grob JJ; Hamid O; Amaravadi R; Simeone E; Wilhelm T; Kim KB; Long GV; Martin AM; Mazumdar J; Goodman VL; Trefzer U
J Clin Oncol; 2013 Sep; 31(26):3205-11. PubMed ID: 23918947
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
7. BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma: Do They Also Differ in Immunohistochemical Assessment and Clinical Features?
Ponti G; Tomasi A; Maiorana A; Ruini C; Maccaferri M; Cesinaro AM; Depenni R; Manni P; Gelsomino F; Giusti F; Garagnani L; Pellacani G
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):30-4. PubMed ID: 26633701
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF mutations in primary melanoma growth rate and survival.
Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
[TBL] [Abstract][Full Text] [Related]
9. BRAF mutation screening in melanoma: is sentinel lymph node reliable?
Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F
Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488
[TBL] [Abstract][Full Text] [Related]
10. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
13. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma.
Anderson S; Bloom KJ; Vallera DU; Rueschoff J; Meldrum C; Schilling R; Kovach B; Lee JR; Ochoa P; Langland R; Halait H; Lawrence HJ; Dugan MC
Arch Pathol Lab Med; 2012 Nov; 136(11):1385-91. PubMed ID: 22332713
[TBL] [Abstract][Full Text] [Related]
14. The \textit{BRAF} V600E mutation in single- institution study of Russian melanoma patients.
Lyubchenko L; Emelyanova M; Shamanin V; Demidov L; Zasedatelev A; Nasedkina T
Cancer Biomark; 2016; 16(1):153-60. PubMed ID: 26600396
[TBL] [Abstract][Full Text] [Related]
15. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
[TBL] [Abstract][Full Text] [Related]
16. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
[TBL] [Abstract][Full Text] [Related]
17. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
[TBL] [Abstract][Full Text] [Related]
18. Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K
Pires da Silva I; Wang KYX; Wilmott JS; Holst J; Carlino MS; Park JJ; Quek C; Wongchenko M; Yan Y; Mann G; Johnson DB; McQuade JL; Rai R; Kefford RF; Rizos H; Scolyer RA; Yang JYH; Long GV; Menzies AM
Clin Cancer Res; 2019 Feb; 25(4):1272-1279. PubMed ID: 30630828
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
20. The molecular profile of metastatic melanoma in Australia.
Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
